Eli Lilly — Oct 30, 2024 release

The following table summarizes the company's 2024 financial guidance: 2024 Guidance (1) Prior Updated (3) Revenue $45.4 to $46.6 billion $45.4 to $46.0 billion (Gross Margin - OPEX (2) ) / Revenue: (reported) 36% to 38% unchanged (non-GAAP) 37% to 39% unchanged Other Income/(Expense) (reported) ($525) to ($425) million ($425) to ($325) million Other Income/(Expense) (non-GAAP) ($400) to ($300) million unchanged Tax Rate Approx. 15% Approx. 17% Earnings per Share (reported) $15.10 to $15.60 $12.05 to $12.55 Earnings per Share (non-GAAP) $16.10 to $16.60 $13.02 to $13.52 (1) Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above. (2) OPEX is defined as the sum of research and development expenses and marketing, selling and administrative expenses. (3) Guidance includes acquired IPR&D charges through Q3 2024 of $3.09 billion or $3.33 on a per share basis. Guidance does not include acquired IPR&D either incurred, or expected to be incurred, after Q3 2024. 11 Webcast of Conference Call As previously announced, investors and the general public can access a live webcast of the Q3 2024 financial results conference call through a link on Lilly's website at investor.lilly.com/webcasts-and-presentations. The conference call will begin at 10 a.m. Eastern time today and will be available for replay via the website. Non-GAAP Financial Measures Certain financial information is presented on both a